Isolation and Characterization of Two Novel Bacteria Afipia cberi and Mesorhizobium hominis from Blood of a Patient Afflicted with Fatal Pulmonary Illness

• Shyh-Ching Lo ,

  * E-mail: shyhching.lo@fda.hhs.gov

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Bingjie Li,

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Guo-Chiuan Hung,

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Haiyan Lei,

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Tianwei Li,

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Jing Zhang,

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Kenjiro Nagamine,

  Current address: Department of Oral & Maxillofacial Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Shien Tsai,

  Affiliation Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America

  ⨯
• Mark J. Zucker,

  Affiliation Department of Medicine, Newark Beth Israel Medical Center, Newark, New Jersey, United States of America

  ⨯
• Ludmilla Olesnicky

  Affiliation Department of Pathology, Newark Beth Israel Medical Center, Newark, New Jersey, United States of America

  ⨯